Cognitive and memory warning letters and litigation trends: Best practices for reducing risk
Asa Waldstein
Guest Article
Cognition and memory products are big business, and the Food and Drug Administration (FDA), National Advertising Division (NAD), Federal Trade Commission (FTC) and plaintiff attorneys are paying attention.
Cognition and memory products are big business, and the Food and Drug Administration (FDA), National Advertising Division (NAD), Federal Trade Commission (FTC) and plaintiff attorneys are paying attention.
This leads to warning letters, competitor challenges and lawsuits, but it can be confusing to know how to discuss ingredients and products without crossing the compliance line or becoming an easy lawsuit target. In this article, I’ll review enforcement trends and best practices to help keep you out of trouble while continuing to educate your consumers and grow your business.